NCT07214129Completed
Safety and Efficacy of Nebulized Nitroglycerin in Pulmonary Arterial Hypertension
Safety and Efficacy of Nebulized Nitroglycerin as a Vaso-reactive Agent in Pulmonary Arterial Hypertension
Source: ClinicalTrials.gov · Last updated 9 Oct 2025
Brief summary (registry, in English)
The 6th World Symposium on Pulmonary Hypertension, pre-capillary pulmonary hypertension (PH) has been defined as mean pulmonary arterial pressure (mPAP) \>20 mm Hg with a pulmonary arterial wedge pressure (PAWP) ≤15 mm Hg and pulmonary vascular resistance (PVR) ≥3 Wood units (WU). The current classification of PH categorizes clinical conditions associated with PH based on similar pathophysiology, etiologies, clinical presentation, hemodynamic characteristics and therapeutic management. PH is classified into five groups. The group 1 pulmonary arterial hypertension (PAH), which comprises of diverse diseases that result in similar pathological changes within the pulmonary vasculature. This includes idiopathic, familial, drug and toxin induced PAH and associated forms of PAH like systemic sclerosis, portal hypertension, congenital heart disease and human immunodeficiency virus (HIV). The remaining 4 groups of PH are secondary to other conditions and are usually referred to as secondary PH
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 2 Oct 2025
- Start date
- 1 Mar 2022
- Primary completion date
- 1 Mar 2023
- Lead sponsor
- Mansoura University
- NCT number
- NCT07214129
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 1 Mar 2022 to the primary completion date, 1 Mar 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- groups 2,3,4,5 Pulmonary hypertension
- Absolute contraindications to pulmonary artery catheter (PAC) placement include: Infection at the insertion site The presence of a right ventricular assist device Insertion during cardiopulmonary bypass Lack of consent
Lab values
- Relative contraindications to the placement of a PAC include a coagulopathy (international normalized ratio \>1.5), thrombocytopenia (platelet count \<50,000/microL), electrolyte disturbances (hypo- or hyper-kalemia, -magnesemia, -natremia, -calcemia), and severe acid-base disturbances (eg, pH \<7.2 or \>7.5).
Other
- Hemodynamic instability.
Who the study is looking for
- All adult patients with clinical and echocardiographic features suggestive of pulmonary hypertension after exclusion of all secondary causes.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mohamed AbdElmoniem Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.